Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Immunogen Inc (IMGN)  
$31.23 0.00 (0.00%) as of 4:30 Thu 2/8


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 264,900,000
Market Cap: 8.27(B)
Last Volume: 49,305,461 Avg Vol: 5,854,790
52 Week Range: $4.32 - $31.23
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  606
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   ImmunoGen is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs). Co.'s main program is mirvetuximab, an ADC targeting folate receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Pivekimab sunirine is an ADC comprised of an antibody designed to target CD123 with site-specific conjugation to a DNA-alkylating payload of the IGN (indolinobenzodiazepine pseudodimer) class. Co.'s pipeline program, IMGC936, is an ADC that is designed to target ADAM9, an enzyme overexpressed in a range of solid tumors and implicated in tumor progression and metastasis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 39,348 1,060,446 4,785,085 4,785,085
Total Sell Value $1,152,494 $23,992,060 $86,338,289 $86,338,289
Total People Sold 4 5 5 5
Total Sell Transactions 4 17 26 26
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 257
  Page 6 of 11  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Wingrove Theresa SVP of Regulatory Affairs   •       –      –    2020-02-24 4 AS $4.99 $80,574 D/D (16,147) 70,498 -4%     
   Barrows Craig Executive VP, General Counsel   •       –      –    2020-02-24 4 AS $4.99 $82,295 D/D (16,492) 145,275 -4%     
   Enyedy Mark J Chief Executive Officer   •       •      –    2020-02-24 4 AS $4.99 $275,558 D/D (55,222) 433,776 -4%     
   Berkenblit Anna SVP & Chief Medical Officer   •       –      –    2020-02-24 4 AS $4.99 $128,757 D/D (25,803) 98,089 -4%     
   Wingrove Theresa VP of Regulatory Affairs   •       –      –    2019-12-31 4 A $1.99 $9,476 D/D 4,762 86,645     -
   Foster David G V.P.-Fin., Prin. Acctg. Off.   •       –      –    2019-12-31 4 A $1.99 $1,317 D/D 662 8,670     -
   Mckee Blaine H. EVP & Chief Business Officer   •       –      –    2019-07-01 4 A $1.84 $9,623 D/D 5,230 5,230     -
   Berkenblit Anna VP & Chief Medical Officer   •       –      –    2019-07-01 4 A $1.84 $9,623 D/D 5,230 123,892     -
   Ryll Thomas VP, Technical Operations   •       –      –    2019-07-01 4 A $1.84 $9,623 D/D 5,230 92,414     -
   Enyedy Mark J Chief Executive Officer   •       •      –    2019-07-01 4 A $1.84 $9,623 D/D 5,230 488,998     -
   Barrows Craig Executive VP, General Counsel   •       –      –    2019-07-01 4 A $1.84 $9,623 D/D 5,230 161,767     -
   Foster David G V.P.-Fin., Prin. Acctg. Off.   •       –      –    2019-07-01 4 A $1.84 $6,506 D/D 3,536 8,008     -
   Gregory Richard J. Executive VP & CSO   •       –      –    2019-01-07 4 AS $5.27 $16,014 D/D (3,038) 236,056     -
   Berkenblit Anna VP & Chief Medical Officer   •       –      –    2019-01-03 4 A $4.08 $10,016 D/D 2,455 135,224     -
   Barrows Craig Executive VP, General Counsel   •       –      –    2019-01-03 4 A $4.08 $10,016 D/D 2,455 171,407     -
   Wingrove Theresa VP of Regulatory Affairs   •       –      –    2019-01-03 4 A $4.08 $9,156 D/D 2,244 92,915     -
   Foster David G V.P.-Fin., Prin. Acctg. Off.   •       –      –    2019-01-03 4 A $4.08 $6,006 D/D 1,472 3,472     -
   Ryll Thomas VP, Technical Operations   •       –      –    2019-01-03 4 A $4.08 $10,016 D/D 2,455 98,679     -
   Enyedy Mark J Chief Executive Officer   •       •      –    2019-01-03 4 A $4.08 $10,016 D/D 2,455 534,838     -
   Goldberg Mark Alan Director   –       •      –    2018-11-06 4 B $5.76 $172,800 D/D 30,000 53,800 2.39     -
   Berkenblit Anna VP & Chief Medical Officer   •       –      –    2018-10-16 4 AS $8.00 $46,808 D/D (5,851) 132,769     -
   Berkenblit Anna VP & Chief Medical Officer   •       –      –    2018-09-10 4 AS $9.46 $55,350 D/D (5,851) 138,620     -
   Johnston David Brannon Chief Financial Officer   •       –      –    2018-06-06 4 AS $11.02 $110,200 D/D (10,000) 180,690     -
   Johnston David Brannon Chief Financial Officer   •       –      –    2018-06-06 4 OE $3.05 $30,500 D/D 10,000 190,690     -
   Junius Daniel M Director   –       •      –    2018-03-16 4 S $12.02 $300,405 D/D (25,000) 184,987     -
  257 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 6 of 11
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us